RedHill Biopharma Advances RHB-102 for GLP-1 GI Side Effects, Plans Phase 2 Study
RDHL sits 23% above its 52-week low of $0.905.
Summary
RedHill Biopharma announced significant progress for its drug candidate RHB-102, including plans for a Phase 2 study targeting gastrointestinal side effects associated with GLP-1 therapies, utilizing an accelerated FDA pathway.
Key Events · Product Development and Regulatory · RDHL
-
RHB-102 Development Progress
RedHill Biopharma announced development progress for RHB-102 (Bekinda®), an advanced clinical-stage, once-daily oral formulation of ondansetron.
-
Targeting GLP-1 Therapy Side Effects
RHB-102 is being developed to address GLP-1/GIP receptor agonist therapy-associated gastrointestinal side effects, such as nausea, vomiting, and diarrhea, which significantly limit the growth of the multi-billion-dollar GLP-1 market.
-
Planned Phase 2 Study
A Phase 2 Proof-of-Concept study for RHB-102 in GLP-1/GIP receptor agonist therapy-associated GI side effects is designed and planned to commence as early as possible this year.
-
Accelerated FDA Pathway
Development is planned under the accelerated FDA 505(b)(2) route, which leverages existing safety and efficacy data for approved drugs.
Analysis · RDHL · Life Sciences
This announcement is highly significant for RedHill Biopharma, a micro-cap company, as it outlines a strategic path for its key pipeline asset, RHB-102, into a potentially massive market. The drug, which has already demonstrated positive Phase 2 and Phase 3 results in other gastrointestinal indications, is now being advanced to address the significant unmet need of GLP-1/GIP therapy-related GI side effects. These side effects are a primary reason for patient discontinuation of popular diabetes and weight-loss drugs, representing a substantial market opportunity. The planned Phase 2 Proof-of-Concept study, coupled with the accelerated FDA 505(b)(2) pathway and expanded intellectual property, provides a clear development roadmap. Successful development in this area could be transformative for the company's future revenue potential and valuation.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1819 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.91 to $6.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.